Ben Hirschler on Muck Rack

Ben Hirschler Verified

London
Pharma, Health and Science Correspondent — Reuters

Pharma, health and science writer at Reuters. Any opinions are mine.

Sep 16, 2014

#Roche CEO tells us his $8B #InterMune acquisition not a signal for more big deals and he "happy" with #Chugai setup reut.rs/1tYVMtq

Sep 16, 2014

Betting on BACE inhibition --> #AstraZeneca to get up to $500M from #Lilly under #Alzheimer's drug partnership deal reut.rs/1yaavo5

Sep 15, 2014

Reuters Farmaceuticals: the drugs fed to farm animals and the risks posed to humans reuters.com/investigates/s… via @SpecialReports

Sep 15, 2014

#Gilead licenses #hepatitis C drug to 7 Indian firms reut.rs/1tVN6UG <--important news but will it ensure comprehensive access?

Sep 15, 2014

Another day, another deal ... #Danaher to buy #Nobel Biocare Holding for $2.2B, including debt reut.rs/1tVhTAV

Sep 15, 2014

RT @epaultaylor: Study suggests a cheaper alternative to a costly eye drug used to treat macular degeneration. By @reutersBenHir feeds.reuters.com/~r/reuters/hea…



Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.

Email

For instructions on how to pitch Ben Hirschler, email reutersbenhir@muckrack.com.


Share This Profile